[{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ABO-101","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona Therapeutics \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona Therapeutics \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"scAAV9.U1a.hSGSH","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"scAAV9.U1a.hSGSH","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV204","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"UX111","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EB-101","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"ABO-504","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"EB-101","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"EB-101","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Prademagene Zamikeracel","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Prademagene Zamikeracel","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Prademagene Zamikeracel","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Prademagene Zamikeracel","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Prademagene Zamikeracel","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Stifel","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Beacon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"AAV204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Beacon Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Abeona Therapeutics \/ Beacon Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by Abeona Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
